Akebia Therapeutics Inc at JPMorgan Healthcare Conference Transcript
All right. Good morning. I'm Eric Joseph, senior biotech analyst at JPMorgan.
And our next presenting company is Akebia Therapeutics. It's my pleasure to welcome CEO, John Butler, to tell us a little bit about the company.
Just as a reminder, the breakout Q&A for this session will be in the Olympic Room.
With that, John?
Eric, thanks so much. Thanks for the opportunity to present this morning.
I just want to remind everyone that I'm going to be making forward-looking statements. So please refer to our SEC filings for more information.
It is very exciting to have the opportunity to talk to you about Akebia today. We are a company with a clear purpose and a clear strategic focus, and that's to better the life of each person impacted by kidney disease.
This is a huge public health issue. There are 37 million Americans who are impacted by
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |